Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma

Cancer

Volumn 95, Issue 11, 2002, Pages 2366-2372

  Pyrhönen, Seppo ^a,b   Hahka Kemppinen, Marjo ^a   Muhonen, Timo ^a   Nikkanen, Väinämö ^b   Eskelin, Sebastian ^a   Summanen, Paula ^a   Tarkkanen, Ahti ^a   Kivel̈, Tero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Dacarbazine; Eye; Interferon; Malignant melanoma; Staging; Systemic chemotherapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; DACARBAZINE; FINNFERON ALPHA; FOTEMUSTINE; HUMAN LEUKOCYTE INTERFERON; INTERFERON; LOMUSTINE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG EFFECT; FATIGUE; FEMALE; FEVER; FIBROSIS; HEART INFARCTION; HUMAN; LEUKOPENIA; MALAISE; MALE; METASTASIS; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THORAX PAIN; THROMBOCYTOPENIA; UVEA MELANOMA; UVEA TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-ALPHA; LOMUSTINE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; TREATMENT OUTCOME; UVEAL NEOPLASMS; VINCRISTINE;

EID: 0036889746     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10996     Document Type: Article

References (31)

1. Shields JA, Shields CL, Donoso LA. Management of posterior uveal melanoma. Surv Ophthalmol. 1991;36:161-195.
2. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS report no. 18. Arch Ophthalmol. 2001;119:969-982.
3. Eskelin S, Pyrhönen S, Summanen P, Hahka-Kemppinen M, Kivelä T. Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology. 2000;107:1443-1449.
4. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383-389.
5. Einhorn LH, Burgess MA, Gottlieb JA. Metastatic patterns of choroidal melanoma. Cancer. 1974;34:1001-1004.
6. Bedikian AY, Kantarjian H, Young SE, Bodey GP. Prognosis in metastatic choroidal melanoma. South Med J. 1981;74: 574-577.
7. Rajpal S, Moore R, Karakousis CP. Survival in metastatic uveal melanoma. Cancer. 1983;52:334-336.
8. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219-2223.
9. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: A review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665-1670.
10. Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: A comparison of patient characteristics and prognosis. Arch Ophthalmol. 1996;114:108.
11. Eskelin S, Summanen P, Pyrhönen S, Tarkkanen A, Kivelä T. Screening for metastatic uveal melanoma revisited. Cancer. 1999;85:1151-1159.
12. Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metastases from ocular melanoma: Imaging study in 110 patients. AJR Am J Roentgenol. 1991;157:1279-1281.
13. The Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119:670-676.
14. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807-810.
15. Nathan FE, Berd D, Sato T, et al. BOLD+interferon in the treatment of metastatic uveal melanoma: First report of active systemic therapy. J Exp Clin Cancer Res. 1997;16:201-208.
16. Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: Review and recommendations. Surv Ophthalmol. 1992;36:429-438.
17. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974-976.
18. Salmon RJ, Levy C, Plancher C, et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol. 1998;24:127-130.
19. Levyraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15:2589-2595.
20. Egerer G, Lehnert T, Max R, Naeher H, Keilholz U, Ho AD. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: A single-center experience with seven patients. Int J Clin Oncol. 2001;6:25-28.
21. Cantore M, Fiorentini G, Aitini E, et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori. 1994;80:37-39.
22. Pyrhönen S, Hahka-Kemppainen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol. 1992;10:1919-1926.
23. Cantell K, Hirvonen S, Koisitinen V. Partial purification of human leukocyte interferon on a large scale. Methods Enzymol. 1981;78:499-505.
24. Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S, Kivelä T. A prognostic model and staging for metastatic uveal melanoma. Cancer. In press.
25. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 48. Geneva: WHO, 1979.
26. National Cancer Institute. Common Toxicity Criteria. Washington, DC: National Cancer Institute, Division of Cancer Treatment, 1998.
27. Schwartz M. Biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272-1294.
28. Hosmer DW, Lemeshow S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York: John Wiley & Sons, 1999.
29. Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer. 1993;72:3091-3098.
30. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
31. Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000; 89:1561-1568.